LLY•prnewswire•
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
Summary
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly's established capabilities in inflammatory-mediated diseases INDIANAPOLIS, Jan. 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 7, 2026 by prnewswire